ストックスクリーナーアプリを入手
19.80
1.18%
0.23
前日終値:
$19.57
開ける：
$19.57
24時間の取引高:
64,625
Relative Volume:
0.45
時価総額：
$290.63M
収益：
-
当期純損益:
$-19.48M
株価収益率:
-12.79
EPS:
-1.5479
ネットキャッシュフロー:
$-8.59M
1週間 パフォーマンス:
-10.00%
1か月 パフォーマンス:
-10.45%
6か月 パフォーマンス:
-21.68%
1年 パフォーマンス:
+76.47%
1日の値動き範囲:
$19.08
$20.28
1週間の範囲:
$17.96
$22.28
52週間の値動き範囲:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
名前
Greenwich Lifesciences Inc
セクター
電話
203-434-3290
住所
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
19.80 | 290.63M | 0 | -19.48M | -8.59M | -1.5479 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-20 | 開始されました | Noble Capital Markets | Outperform |
| 2021-09-01 | 開始されました | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc (GLSI) 最新ニュース
Greenwich Lifesciences Receives European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 - marketscreener.com
Greenwich LifeSciences stock jumps as EMA approves commercial GP2 By Investing.com - Investing.com South Africa
Greenwich LifeSciences stock jumps as EMA approves commercial GP2 - Investing.com
Sector Update: Healthcare - Moomoo
Greenwich LifeSciences Says Commercially Manufactured GP2 Cleared for Trial in Europe - Moomoo
European regulators authorize Greenwich LifeSciences to deploy commercial GP2 in FLAMINGO-01 study - Traders Union
Greenwich LifeSciences Announces EMA Approval for Commercially Manufactured GP2 in FLAMINGO-01 Across Europe - Quiver Quantitative
Europe joins U.S. in using commercial GP2 for Greenwich’s breast cancer trial - Stock Titan
Greenwich Lifesciences Inc announced that its commercial production of Gp2 has been approved for use in the Flamingo-01 study in Europe. - Bitget
The Technical Signals Behind (GLSI) That Institutions Follow - Stock Traders Daily
GLSIGreenwich LifeSciences Inc Latest SEC Filings - Finviz
GREENWICH LIFESCIENCES INC (GLSI) Stock Chart - ChartMill
Greenwich LifeSciences, Inc. Financial Disclosures & SEC Filings - TradingView
GLSI Q1 2026 Earnings: Miss on EPS Estimates, No Revenue Reported; Stock Edges UpTangible Book Value - dars.gov.et
Greenwich LifeSciences (GLSI) Surges 8% as Biotech Stock Tests Key Resistance Near $20.79Mean Reversion Trade - dars.gov.et
Price to book forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView
Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones - Stock Traders Daily
Greenwich LifeSciences, Inc. Actuals & Estimates (NASDAQ:GLSI) - TradingView
GLSI Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView
Price to sales forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView
Price to earnings forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView
Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Greenwich Lifesciences Inc (GLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Greenwich Lifesciences Inc (GLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Greenwich Lifesciences Inc (GLSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Greenwich Lifesciences Inc (GLSI) Institutional Confidence - TradingKey
Greenwich Lifesciences Inc (GLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Greenwich Lifesciences Inc (GLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Greenwich Lifesciences Inc (GLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GLSI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GLSI Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D Investment - newsline.com
Technical Reactions to GLSI Trends in Macro Strategies - Stock Traders Daily
Greenwich LifeSciences (GLSI) Rises 4.47% as Shares Approach $25 ResistanceTechnical Analysis Picks - newsline.com
Greenwich LifeSciences, Inc. Q1 2026 Quarterly Report: Financials, Risk Factors, and Disclosure Highlights - Minichart
Trading the Move, Not the Narrative: (GLSI) Edition - Stock Traders Daily
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Greenwich LifeSciences (GLSI) loss widens as ATM equity raises fund trials - Stock Titan
What’s Driving GLSI Stock Today? - Stocktwits
Noble Financial Reaffirms Their Buy Rating on Greenwich LifeSciences (GLSI) - The Globe and Mail
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Noble Financial Maintains Greenwich LifeSciences(GLSI.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Greenwich LifeSciences, Inc. 2024 Annual Report: Breast Cancer Immunotherapy Pipeline, Clinical Trials, and Regulatory Risks - minichart.com.sg
GREENWICH LIFESCIENCES ($GLSI) Releases Q4 2025 Earnings - Quiver Quantitative
Greenwich LifeSciences FY 2025: Net loss $19.4M, No revenue — 10-K Summary - TradingView
Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Greenwich LifeSciences delays 10-K filing, cites audit coordination By Investing.com - Investing.com Nigeria
Greenwich LifeSciences presents immune response data at ASCO - Investing.com
Greenwich LifeSciences presents immune response data at ASCO By Investing.com - Investing.com South Africa
Breast cancer trial: GLSI-100 shots spark injection-site reactions over time - Stock Titan
Greenwich Lifesciences Inc (GLSI) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):